Pharma Developer Licenses Patent for Treating Neuroendocrine Cancers from US Ivy League College
Pharma Developer Licenses Patent for Treating Neuroendocrine …
Streetwise Live! – Algernon Pharmaceuticals CEO Christopher Moreau and Dr. David Nutt Discuss Phase 1 DMT Study For Stroke
Algernon Pharmaceuticals Inc. CEO Christopher J. Moreau and …
Proactive Investors Interview – Algernon Pharmaceuticals Phase 2 Human Study of Ifenprodil for IPF and Chronic Cough is Now 70% Enrolled
Algernon Pharmaceuticals (CSE: AGN – OTCQB: AGNPF) CEO …
Stockhouse – Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke
Finding an effective method of preventing the possibility of stroke …
Proactive Investors Interview – Algernon Pharmaceuticals Launches Ifenprodil Pancreatic Cancer Clinical Research Program
Algernon Pharmaceuticals Launches Ifenprodil Pancreatic Cancer …
Weekend Dispensary – Could the ‘spirit molecule’ be a treatment option for stroke?
Could the ‘spirit molecule’ be a treatment option for stroke? …
Psychedelic Finance – Interview with Dr. Rick Strassman | DMT Stroke Program Consultant, Algernon Pharmaceuticals
Rick Strassman is an American clinical associate professor of …
Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke Receives Positive FDA Feedback
Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke …
PRMediaNow Algernon Pharmaceuticals Update with CEO Christopher Moreau
PRMediaNow Algernon Pharmaceuticals Update with CEO Christopher …
Proactive Interview regarding 50% enrollment into the IPF/Chronic Cough
Algernon Pharmaceuticals has now enrolled 50% of patients for its …
Psychedelic Finance – Interview with Professor David Nutt | Algernon Pharmaceuticals DMT Stroke Consultant
Psychedelic Finance – Interview with Professor David Nutt | …
Interview with Algernon Pharmaceuticals CEO Christopher J. Moreau About New DMT Stroke Program
Interview with Algernon Pharmaceuticals CEO Christopher J. Moreau …
Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau
Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO …
DMT Update and Recap Interview with CEO Christopher Moreau and Host Cyndi Edwards of PRmediaNow
Algernon Pharmaceuticals CEO, Christopher J. Moreau joins …
Could the “Spirit Molecule” DMT Assist in Stroke Recovery? – Technology Network
Could the “Spirit Molecule” DMT Assist in Stroke Recovery? …
Algernon CEO Christopher Moreau and Consultant Dr. David Nutt Discuss the DMT Stroke Program on BioPub Webcast Hosted by Dr. KSS MD, PhD
Algernon CEO Christopher Moreau and Consultant Dr. David Nutt Discuss …
Algernon Pharmaceuticals Looks to Highly Regarded UK Company to Conduct Phase 1 DMT Stroke Study
Algernon Pharmaceuticals Looks to Highly Regarded UK Company to …
Microdose PsyCap Conference: Investment Opportunities and New Companies in the Sector
Microdose PsyCap Conference: Investment Opportunities and New …
Psychedelic Capital Virtual Investment Conference – Feb 2021 | Microdose
Algernon Pharmaceuticals CEO Christopher J. Moreau at Psychedelic …
BNN Bloomberg – How Algernon Pharmaceuticals is aiming to use psychedelics to aid stroke recovery
How Algernon Pharmaceuticals is aiming to use psychedelics to …
Proactive – Algernon Pharmaceuticals considers adding lung scarring for additional endpoint in Ifenprodil study
Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher …
IFL Science – Psychedelic Drug DMT To Be Trialed On Stroke Victims
Psychedelic Drug DMT To Be Trialed On Stroke Victims …
Stroke victims to get hallucinogenic drug DMT to stave off worst effects of life-threatening condition in first-of-its-kind trial, scientists say
Stroke victims to get hallucinogenic drug DMT to stave off worst …
Metro UK – Stroke victims to be given psychedelic drug DMT in groundbreaking study
Psychedelic drug DMT could help stroke victims recover by rewiring …
Algernon Pharmaceuticals Launches Research Program for Treatment of Stroke Using Psychedelic Drug DMT
Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO …
DMT Stroke Research: Algernon Pharmaceuticals Moving to the Head of the Pack
In this interview, Andrew O’Donnell is joined by …
Algernon Pharmaceuticals Targets Psychedelic Drug DMT for Stroke Program
Algernon Pharmaceuticals CEO, Christopher J. Moreau and CSO, …
StreetSmart Live! Interview with CEO, Christopher Moreau and CSO, Dr. Mark Williams
Algernon Pharmaceuticals CEO, Christopher Moreau and CSO, Dr. Mark …
A Letter From Algernon Pharmaceuticals CEO Christopher Moreau
December 8, 2020, Dear Algernon Newsletter Subscriber: I would like …
Algernon Pharmaceuticals CEO Christopher Moreau to present at Proactive’s One2One Virtual Investor Conference to be held December 8, 2020
Algernon Pharmaceuticals Inc. (CSE:AGN) (OTCQB:AGNPF) CEO Christopher …
CEO Christopher Moreau joined Steve Darling from Proactive to discuss how the company has enrolled the final patient in its multinational Phase 2b/3 human study
Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher …
CEO Christopher Moreau discusses enrollment of its 154th patient in human study
Algernon Pharmaceuticals (CSE:AGN-OTCQB: AGNPF) CEO Christopher …
Algernon Pharmaceuticals to provide interim data from Ifenprodil Phase 2b/3 human study
Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO …
Proactive Investor – Interview with CEO Christopher Moreau regarding the approval from the Data and Safety Monitoring Board to continue the study
Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO Christopher …